← All trials
NCT05259631
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2022
- Primary completion
- Feb 25, 2025
- Completion date
- Feb 25, 2026
- First posted
- Feb 28, 2022
- Last posted
- Apr 5, 2022
- Enrollment
- 310
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Negovsky Reanimatology Research InstituteLead sponsor
- Negovsky Reanimatology Research InstituteOverall official - principal investigator
- Negovsky Reanimatology Research InstituteReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.